Robert Juba | Vice President Of Biological Manufacturing And Clinical Supply Management
inovio

Robert Juba, Vice President Of Biological Manufacturing And Clinical Supply Management, inovio

Mr. Juba is responsible for ensuring the manufacturing and supply of Inovio’s SynCon® plasmid DNA therapeutic and prophylactic vaccine candidates for clinical use. He provides strategic and operational leadership of Supply Operations function, establishing supply processes, planning, procurement, and inventory strategies for late-stage clinical programs as well as new product launches and product line extensions.

As a chemical engineer with 20+ years of experience managing cGMP pharmaceutical and biological vaccine manufacturing for commercial and clinical products, Mr. Juba leads with extensive technical expertise to help Inovio reach product development and commercialization goals. He previously led plasmid manufacturing at VGXI, Inc. and held several positions at Merck in bulk vaccine manufacturing operations and strategy. Mr. Juba holds a Master of Science degree in Chemical Engineering Practice and a BS degree in Chemical Engineering, both from the Massachusetts Institute of Technology.

Appearances:



Day 3, September 30th @ 13:40

Interactive panel: Unique rapid production opportunities and challenges that face nucleic acid-based vaccine manufacture and delivery

  • Why and where will it make a difference?
  • How is it different to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
  • How will RNA vaccines help in an outbreak like SARS-CoV-2? Can the scale-up/volume be big enough?
  • Does the speed and dosage have an effect on the overall quality of the vaccine?
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT

back to speakers